Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca's Imfinzi/Tremelimumab Combo Conquers HIMALAYA

Improves Overall Survival In Liver Cancer Patients

Executive Summary

After the combination's success in the non-small cell lung cancer POSEIDON study, AstraZeneca's Imfinzi and tremelimumab could now be on the way to approval as a first-line treatment for hepatocellular carcinoma.

You may also be interested in...



AstraZeneca Uses Priority Voucher To Speed Combo Towards Liver Cancer Approval

AstraZeneca’s PD-L1/CTLA-4 combination could soon be rivalling Roche’s regimen, and may offer greater safety and tolerability for liver cancer patients.

AstraZeneca Signs First COVID-19 Vaccine For-Profit Deals

AstraZeneca is one of the sector’s top growth stories in 2021, but controversies around its COVID-19 vaccine continue to grab headlines, and Chinese price cuts bite.

AstraZeneca’s Imfinzi Fails Again In Head And Neck Cancer

The Phase III KESTREL study evaluating Imfinzi missed its primary overall survival benefit and a key secondary outcome in first-line recurrent or metastatic head and neck squamous cell carcinoma.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel